13F Holdings
中文EN

SLN Silence Therapeutics plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1479615

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-98.2%
TTM net income YoY20.3%
TTM EPS YoY22.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin95.0%
Operating margin-12,343.6%
Net margin-11,276.5%
FCF margin-9,681.6%
EBITDA margin-12,279.2%

Returns

ROE-35.6%
ROA-24.0%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.6%
Debt / equity0.00x
Current ratio23.94x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USDFY20232023-12-31 · USDFY20222022-12-31 · GBPFY2021*2021-12-31 · GBP
Income statement
Revenue$559,000$43.26M$31.64M17.50M12.41M
Cost of revenue$215,000$11.81M$12.87M10.88M7.46M
Gross profit$344,000$31.45M$18.78M6.62M4.96M
R&D expense$67.75M$67.88M$56.94M35.60M30.77M
SG&A expense$22.34M$26.88M$26.22M19.61M20.01M
Operating income-$91.08M-$63.32M-$64.38M-48.59M-45.81M
Interest expense——2.15MGBP47,00052,000
Pretax income-$88.60M-$44.46M-$53.27M-47.37M-45.86M
Income tax$11,000$845,000$956,000-6.88M-6.45M
Net income-$88.61M-$45.31M-$54.23M-$50.33MUSD-39.41M
EBITDA-$90.77M-$62.98M-$64.01M——
EPS (basic)-0.63-0.33-0.49-0.52USD—
EPS (diluted)-0.63-0.33-0.49-0.52USD—
Weighted avg. shares (diluted)141.69M138.75M111.28M96.58M—
Banking
Net interest income——67,000GBP23,00010,000
Balance sheet
Cash & equivalents$11.28M$121.33M$68.79M54.82M73.54M
Short-term investments$73.84M$26.00M———
Receivables$0$972,000$290,000915,000331,000
Current assets$118.66M$187.37M$103.15M96.69M86.33M
PP&E, net$1.58M$1.82M$1.94M2.20M1.94M
Goodwill$10.62M$9.39M$9.98M8.01M7.59M
Intangibles$288,000$312,000———
Total assets$131.44M$202.63M$119.45M——
Current liabilities$13.61M$16.82M$22.34M21.94M15.17M
Total liabilities$69.14M$68.61M$97.45M——
Shareholders' equity$62.30M$134.02M$21.99M$27.22MUSD$12.37MUSD
Shares outstanding141.70M141.67M118.85M107.81M—
Cash flow statement
Operating cash flow-$62.27M-$67.64M-$49.46M-45.46M6.81M
Capital expenditure$55,000$211,000$56,000140,0001.31M
Free cash flow-$62.33M-$67.85M-$49.52M-45.60M5.50M
Investing cash flow-$47.99M-$21.97M$19.29M-16.54M8.68M
Financing cash flow$15,000$142.09M$31.94M43.05M30.71M
Depreciation & amortization$312,000$336,000$369,000$379,000USD—
Stock-based compensation$8.07M$16.31M$16.27M10.25M8.63M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.